PART I . Overview Class-Leading GSK-3 Inhibitor We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib, an ATP-competitive small molecule that is designed to enter cancer cells and block the function of the enzyme glycogen synthase kinase-3 beta (GSK-3), a master regulator of complex biological signaling cascades, inclu...
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001683168-26-002257 | EDGAR | 79K words |
| 2025-03-13 | 2024-12-31 | 0001683168-25-001581 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001683168-25-008323 | EDGAR | 24K words |
| 2025-08-14 | 2025-06-30 | 0001683168-25-006159 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001683168-25-003705 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001683168-24-007971 | EDGAR | — |
| 2024-09-24 | 2024-06-30 | 0001683168-24-006623 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-01-12 | 0001683168-26-000217 | EDGAR | 1K words |
| 2025-11-28 | 0001683168-25-008732 | EDGAR | — |
| 2025-11-21 | 0001683168-25-008618 | EDGAR | — |
| 2025-09-10 | 0001683168-25-006831 | EDGAR | — |
| 2025-06-26 | 0001683168-25-004766 | EDGAR | — |
| 2025-06-05 | 0001683168-25-004258 | EDGAR | — |
| 2025-06-02 | 0001683168-25-004117 | EDGAR | — |
| 2025-05-23 | 0001683168-25-003995 | EDGAR | — |
| 2025-05-06 | 0001683168-25-003163 | EDGAR | — |
| 2025-03-28 | 0001683168-25-001945 | EDGAR | — |
36 total filings indexed. 19 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001652935 |
| Ticker | ACTU |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.actuatetherapeutics.com |
| Listed | 2024-08-13 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report